Expand, Acquire, Develop
and Identify.

These are the four key elements of our growth strategy. Cumberland Pharmaceuticals is a unique company with quality products that deliver real patient solutions every day.

Our strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products.

We believe that exploring opportunities to expand the market potential for our existing commercial stage products represents our lowest risk growth strategy.  The Company is continually evaluating new opportunities to further the clinical development of our products, whether by exploring new potential indications to expand labeling and help new patient populations or by developing new clinical data to further support our existing markets and the efforts of our commercial organization.

The Company focuses on the hospital acute care, gastroenterology and oncology market segments that both feature concentrated prescriber bases. Our sales and marketing efforts are focused on expanding our reach within the medical community and keeping healthcare providers informed of how our products are able to improve the quality of care for their patients. The combination of our ongoing development activities and marketing efforts drives the success of our products.

We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties.

Another component of our growth strategy is to acquire approved brands that serve patient populations that our sales and marketing team can effectively reach. We seek proprietary products that provide a differentiated benefit to patients. In addition, we target products that could benefit from the promotional capabilities of our sales and marketing organization or that could be expanded to help new patient groups through the efforts of our development team.

Where appropriate, Cumberland is poised to acquire and negotiate rights to those products to support and commercialize them. In acquiring these already approved products, we are able to add to our growing portfolio to meet the needs of patients.

Our team is developing a pipeline of new product candidates to address unmet medical needs.

Our business development efforts are led by a multi-disciplinary team with significant pharmaceutical and transactional expertise.  We proactively seek out and evaluate product candidates from a variety of sources, including our international network of advisors.  Highly critical selection criteria guide our acquisition strategy as we pursue new development stage assets that fit our medical expertise and commercial capabilities.  We believe our current product portfolio is representative not only of our discriminating efforts but also of the types of opportunities we seek.

These efforts allow Cumberland to selectively build a portfolio of differentiated, safe, and effective products for underserved patient populations.

Cumberland is also focused on identifying earlier stage product candidates that have the potential to improve patient care.

Our majority-owned subsidiary, Cumberland Emerging Technologies (CET) is for just that purpose. We supplement our acquisition and late-stage development initiatives with CET’s early-stage drug development activities. CET represents a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, the state of Tennessee supported LaunchTN, and WinHealth Pharma. The mission of CET is to identify promising new biomedical products and advance them towards the marketplace.

At CET we have established a series of collaboration agreements with a select group of academic research institutions located across the mid-south region of the U.S. We work with our university partners to identify and establish arrangements for each new product candidate. We then team with the university scientific team to support product development and also identify opportunities to secure grant funding.

O